Iranian Red Crescent Medical Journal

Published by: Kowsar

Xenotropic Murine Leukemia Virus-Related Virus and RNase L R462Q Variants in Iranian Patients With Sporadic Prostate Cancer

Farhad Babaei 1 , 2 , Ali Ahmadi 3 , Farhad Rezaei 1 , Somayeh Jalilvand 1 , Nastaran Ghavami 1 , Mahmoud Mahmoudi 4 , Ramin Abiri 2 , Nasim Kondori 5 , Rakhshande Nategh 1 and Talat Mokhtari Azad 1 , *
Authors Information
1 Department of Virology, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
2 Department of Microbiology, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, IR Iran
3 Department of Pathology, School of Medicine, Tehran University of Medical Sciences, Tehran, IR Iran
4 Department of Statistics, School of Public Health, Tehran University of Medical Sciences, Tehran, IR Iran
5 Department of Pediatrics, School of Medicine, Kermanshah University of Medical Sciences, Kermanshah, IR Iran
Article information
  • Iranian Red Crescent Medical Journal: December 01, 2015, 17 (12); e19439
  • Published Online: December 19, 2015
  • Article Type: Research Article
  • Received: April 13, 2014
  • Revised: May 20, 2014
  • Accepted: June 15, 2014
  • DOI: 10.5812/ircmj.19439

To Cite: Babaei F, Ahmadi A, Rezaei F, Jalilvand S, Ghavami N, et al. Xenotropic Murine Leukemia Virus-Related Virus and RNase L R462Q Variants in Iranian Patients With Sporadic Prostate Cancer, Iran Red Crescent Med J. 2015 ; 17(12):e19439. doi: 10.5812/ircmj.19439.

Abstract
Copyright © 2015, Iranian Red Crescent Medical Journal. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011; 61(2): 69-90[DOI][PubMed]
  • 2. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010; 127(12): 2893-917[DOI][PubMed]
  • 3. IARC. Section of Cancer Information. Lyonn; Scientific Publications. 2008;
  • 4. Chan JM, Giovannucci EL. Diet: Dairy Products, Calcium, and Vitamin D and Risk of Prostate Cancer. Epidemiologic Rev. 2001; 23(1): 87-92[DOI]
  • 5. Hayes RB, Pottern LM, Strickler H, Rabkin C, Pope V, Swanson GM, et al. Sexual behaviour, STDs and risks for prostate cancer. Br J Cancer. 2000; 82(3): 718-25[DOI][PubMed]
  • 6. Kolonel LN. Fat, meat, and prostate cancer. Epidemiol Rev. 2001; 23(1): 72-81[PubMed]
  • 7. Casey G, Neville PJ, Plummer SJ, Xiang Y, Krumroy LM, Klein EA, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet. 2002; 32(4): 581-3[DOI][PubMed]
  • 8. Downing SR, Russell PJ, Jackson P. Alterations of p53 are common in early stage prostate cancer. Can J Urol. 2003; 10(4): 1924-33[PubMed]
  • 9. Jonsson BA, Adami HO, Hagglund M, Bergh A, Goransson I, Stattin P, et al. -160C/A polymorphism in the E-cadherin gene promoter and risk of hereditary, familial and sporadic prostate cancer. Int J Cancer. 2004; 109(3): 348-52[DOI][PubMed]
  • 10. Carpten J, Nupponen N, Isaacs S, Sood R, Robbins C, Xu J, et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat Genet. 2002; 30(2): 181-4[DOI][PubMed]
  • 11. Rennert H, Bercovich D, Hubert A, Abeliovich D, Rozovsky U, Bar-Shira A, et al. A novel founder mutation in the RNASEL gene, 471delAAAG, is associated with prostate cancer in Ashkenazi Jews. Am J Hum Genet. 2002; 71(4): 981-4[DOI][PubMed]
  • 12. Rokman A, Ikonen T, Seppala EH, Nupponen N, Autio V, Mononen N, et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am J Hum Genet. 2002; 70(5): 1299-304[DOI][PubMed]
  • 13. Downing SR, Hennessy KT, Abe M, Manola J, George DJ, Kantoff PW. Mutations in ribonuclease L gene do not occur at a greater frequency in patients with familial prostate cancer compared with patients with sporadic prostate cancer. Clin Prostate Cancer. 2003; 2(3): 177-80[PubMed]
  • 14. Maier C, Haeusler J, Herkommer K, Vesovic Z, Hoegel J, Vogel W, et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer. 2005; 92(6): 1159-64[DOI][PubMed]
  • 15. Wiklund F, Jonsson BA, Brookes AJ, Stromqvist L, Adolfsson J, Emanuelsson M, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res. 2004; 10(21): 7150-6[DOI][PubMed]
  • 16. Nakazato H, Suzuki K, Matsui H, Ohtake N, Nakata S, Yamanaka H. Role of genetic polymorphisms of the RNASEL gene on familial prostate cancer risk in a Japanese population. Br J Cancer. 2003; 89(4): 691-6[DOI][PubMed]
  • 17. Shook SJ, Beuten J, Torkko KC, Johnson-Pais TL, Troyer DA, Thompson IM, et al. Association of RNASEL variants with prostate cancer risk in Hispanic Caucasians and African Americans. Clin Cancer Res. 2007; 13(19): 5959-64[DOI][PubMed]
  • 18. Xiang Y, Wang Z, Murakami J, Plummer S, Klein EA, Carpten JD, et al. Effects of RNase L mutations associated with prostate cancer on apoptosis induced by 2',5'-oligoadenylates. Cancer Res. 2003; 63(20): 6795-801[PubMed]
  • 19. Urisman A, Molinaro RJ, Fischer N, Plummer SJ, Casey G, Klein EA, et al. Identification of a novel Gammaretrovirus in prostate tumors of patients homozygous for R462Q RNASEL variant. PLoS Pathog. 2006; 2(3)[DOI][PubMed]
  • 20. Arnold RS, Makarova NV, Osunkoya AO, Suppiah S, Scott TA, Johnson NA, et al. XMRV infection in patients with prostate cancer: novel serologic assay and correlation with PCR and FISH. Urology. 2010; 75(4): 755-61[DOI][PubMed]
  • 21. Danielson BP, Ayala GE, Kimata JT. Detection of xenotropic murine leukemia virus-related virus in normal and tumor tissue of patients from the southern United States with prostate cancer is dependent on specific polymerase chain reaction conditions. J Infect Dis. 2010; 202(10): 1470-7[DOI][PubMed]
  • 22. Schlaberg R, Choe DJ, Brown KR, Thaker HM, Singh IR. XMRV is present in malignant prostatic epithelium and is associated with prostate cancer, especially high-grade tumors. Proc Natl Acad Sci U S A. 2009; 106(38): 16351-6[DOI][PubMed]
  • 23. Fischer N, Hellwinkel O, Schulz C, Chun FK, Huland H, Aepfelbacher M, et al. Prevalence of human gammaretrovirus XMRV in sporadic prostate cancer. J Clin Virol. 2008; 43(3): 277-83[DOI][PubMed]
  • 24. Hohn O, Krause H, Barbarotto P, Niederstadt L, Beimforde N, Denner J, et al. Lack of evidence for xenotropic murine leukemia virus-related virus(XMRV) in German prostate cancer patients. Retrovirology. 2009; 6: 92[DOI][PubMed]
  • 25. Rezaei SD, Hearps AC, Mills J, Pedersen J, Tachedjian G. No association between XMRV or related gammaretroviruses in Australian prostate cancer patients. Virol J. 2013; 10: 20[DOI][PubMed]
  • 26. Sakuma T, Hue S, Squillace KA, Tonne JM, Blackburn PR, Ohmine S, et al. No evidence of XMRV in prostate cancer cohorts in the Midwestern United States. Retrovirology. 2011; 8: 23[DOI][PubMed]
  • 27. Switzer WM, Jia H, Zheng H, Tang S, Heneine W. No association of xenotropic murine leukemia virus-related viruses with prostate cancer. PLoS One. 2011; 6(5)[DOI][PubMed]
  • 28. Fredricks DN, Relman DA. Paraffin removal from tissue sections for digestion and PCR analysis. Biotechniques. 1999; 26(2): 198-200[PubMed]
  • 29. Jalilvand S, Tornesello ML, Buonaguro FM, Buonaguro L, Naraghi ZS, Shoja Z, et al. Molecular epidemiology of human herpesvirus 8 variants in Kaposi's sarcoma from Iranian patients. Virus Res. 2012; 163(2): 644-9[DOI][PubMed]
  • 30. Sato Y, Sugie R, Tsuchiya B, Kameya T, Natori M, Mukai K. Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn Mol Pathol. 2001; 10(4): 265-71[PubMed]
  • 31. Reza M, Fahimeh G, Mollaiea HR. Evaluation of Xenotropic Murine Leukemia Virus and its R426Q Polymorphism in Patients with Prostate Cancer in Kerman, Southeast of Iran. Asian Pacific Journal of Cancer Prevention. 2012; 13(8): 3669-73[DOI]
  • 32. Garson JA, Kellam P, Towers GJ. Analysis of XMRV integration sites from human prostate cancer tissues suggests PCR contamination rather than genuine human infection. Retrovirology. 2011; 8: 13[DOI][PubMed]
  • 33. Hue S, Gray ER, Gall A, Katzourakis A, Tan CP, Houldcroft CJ, et al. Disease-associated XMRV sequences are consistent with laboratory contamination. Retrovirology. 2010; 7(1): 111[DOI][PubMed]
  • 34. Oakes B, Tai AK, Cingoz O, Henefield MH, Levine S, Coffin JM, et al. Contamination of human DNA samples with mouse DNA can lead to false detection of XMRV-like sequences. Retrovirology. 2010; 7: 109[DOI][PubMed]
  • 35. Meyer MS, Penney KL, Stark JR, Schumacher FR, Sesso HD, Loda M, et al. Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis. 2010; 31(9): 1597-603[DOI][PubMed]
  • 36. Li H, Tai BC. RNASEL gene polymorphisms and the risk of prostate cancer: a meta-analysis. Clin Cancer Res. 2006; 12(19): 5713-9[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiation Alert
via Google Reader

Readers' Comments